Floatz logo

Bb-Mpi-03

Small-cell Lung Cancer

Sellas Life Sciences Groupprotein_peptidePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Small-cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Lurbinectedin
Sichuan University
Phase 3BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB
(+)-VINCRISTINE
PharmaMar
Phase 3B
AMRUBICIN
Sumitomo Pharma Co., Ltd.
Phase 3B
Abemaciclib
Case Comprehensive Cancer Center
Phase 2B

View all 47 →

Same molecule, other indications

Bb-Mpi-03 is also rated in:

Acute Myeloid LeukemiaDormant
B
Indicative ·
58 / 100
View asset →
Acute Lymphoblastic LeukemiaDormant
CCC
Indicative ·
51 / 100
View asset →
Ovarian CancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →